BACKGROUND: The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) is very active in patients with advanced-stage Hodgkin's lymphoma, albeit at the expense of severe toxicities. Individual patients might be cured with less burdensome therapy. We investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it for PET-2-negative patients. METHODS: In this open-label, randomised, parallel-group phase 3 trial, we recruited patients aged 18-60 years with newly diagnosed, advanced-stage Hodgkin's lymphoma in 301 hospitals and private practices in Germany, Switzerland, Austria, the Netherlands, and the Czech Republic. After central review of PET-2, patients were assigned (1:1) to one of two parallel treatment groups on the basis of their PET-2 result. Patients with positive PET-2 were randomised to receive six additional cycles of either standard eBEACOPP (8 × eBEACOPP in total) or eBEACOPP with rituximab (8 × R-eBEACOPP). Those with negative PET-2 were randomised between standard treatment with six additional cycles of eBEACOPP (8 × eBEACOPP) or experimental treatment with two additional cycles (4 × eBEACOPP). A protocol amendment in June, 2011, introduced a reduction of standard therapy to 6 × eBEACOPP; after this point, patients with positive PET-2 were no longer randomised and were all assigned to receive 6 × eBEACOPP and patients with negative PET-2 were randomly assigned to 6 × eBEACOPP (standard) or 4 × eBEACOPP (experimental). Randomisation was done centrally using the minimisation method including a random component, stratified according to centre, age (<45 vs ≥45 years), stage (IIB, IIIA vs IIIB, IV), international prognostic score (0-2 vs 3-7), and sex. eBEACOPP was given as previously described; rituximab was given intravenously at a dose of 375 mg/m2 (maximum total dose 700 mg). The primary objectives were to show superiority of the experimental treatment in the PET-2-positive cohort, and to show non-inferiority of the experimental treatment in the PET-2-negative cohort in terms of the primary endpoint, progression-free survival. We defined non-inferiority as an absolute difference of 6% in the 5-year progression-free survival estimates. Primary analyses in the PET-2-negative cohort were per protocol; all other analyses were by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT00515554. FINDINGS: Between May 14, 2008, and July 18, 2014, we recruited 2101 patients, of whom 137 were found ineligible before randomisation and a further 19 were found ineligible after randomisation. Among 434 randomised patients (217 per arm) with positive PET-2, 5-year progression-free survival was 89·7% (95% CI 85·4-94·0) with eBEACOPP and 88·1% (83·5-92·7) with R-eBEACOPP (log-rank p=0·46). Patients with negative PET-2 randomly assigned to either 8 × eBEACOPP or 6 × eBEACOPP (n=504) or 4 × eBEACOPP (n=501) had 5-year progression-free survival of 90·8% (95% CI 87·9-93·7) and 92·2% (89·4-95·0), respectively (difference 1·4%, 95% CI -2·7 to 5·4). 4 × eBEACOPP was associated with fewer severe infections (40 [8%] of 498 vs 75 [15%] of 502) and organ toxicities (38 [8%] of 498 vs 91 [18%] of 502) than were 8 × eBEACOPP or 6 × eBEACOPP in PET-2-negative patients. Ten treatment-related deaths occurred: four in the PET-2-positive cohort (one [<1%] in the 8 × eBEACOPP group, three [1%] in the 8 × R-eBEACOPP group) and six in the PET-2-negative group (six [1%] in the 8 × eBEACOPP or 6 × eBEACOPP group). INTERPRETATION: The favourable outcome of patients treated with eBEACOPP could not be improved by adding rituximab after positive PET-2. PET-2 negativity allows reduction to only four cycles of eBEACOPP without loss of tumour control. PET-2-guided eBEACOPP provides outstanding efficacy for all patients and increases overall survival by reducing treatment-related risks for patients with negative PET-2. We recommend this PET-2-guided treatment strategy for patients with advanced-stage Hodgkin's lymphoma. FUNDING: Deutsche Krebshilfe, Swiss State Secretariat for Education and Research, and Roche Pharma AG.

3rd Medical Department Paracelcus Medical University and Salzburg Cancer Research Institute Salzburg Austria; Salzburg Cancer Research Institute and AGMT Salzburg Austria

Berlin Reference Center for Lymphoma and Haematopathology Berlin Germany

Cantonal Hospital Baselland Liestal Switzerland; Swiss Group for Clinical Cancer Research Bern Switzerland

Department of Haematology and Oncology Robert Bosch Hospital Stuttgart Germany

Department of Haematology Asklepios Hospital St Georg Hamburg Germany

Department of Haematology Oncology and Palliative Care Ernst von Bergmann Hospital Potsdam Germany

Department of Haematology University Hospital University Duisburg Essen Essen Germany

Department of Hematology and Oncology Charité University of Medicine Berlin Germany

Department of Hematology Oncology University Hospital of Munich Munich Germany

Department of Internal Medicine 1 Klinikum Bremen Mitte Bremen Germany

Department of Internal Medicine 3 Klinikum Rechts der Isar Munich Germany

Department of Internal Medicine 3 Städtisches Klinikum Karlsruhe Karlsruhe Germany

Department of Internal Medicine 3 University Hospital of Ulm Ulm Germany

Department of Internal Medicine 5 University of Heidelberg Heidelberg Germany

Department of Internal Medicine Hematology University Hospital Kralovske Vinohrady 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Nuclear Medicine University Hospital of Cologne Cologne Germany

Department of Oncology and Haematology University Hospital Hamburg Eppendorf Hamburg Germany

Department of Oncology and Haematology University Hospital Mainz Mainz Germany

Department of Oncology and Haematology University of Tübingen Tübingen Germany

Department of Radiotherapy University Hospital of Cologne Cologne Germany

Department of Radiotherapy University Hospital of Muenster Muenster Germany

German Hodgkin Study Group Department of Internal Medicine 1 University Hospital of Cologne Cologne Germany

HELIOS Medical Center Berlin Buch Berlin Germany

Karl Lennert Cancer Center University Hospital Schleswig Holstein Kiel Germany

Medizinische Klinik und Poliklinik 2 Universitätsklinikum Würzburg Würzburg Germany

Salzburg Cancer Research Institute and AGMT Salzburg Austria; Medical University Innsbruck Internal Medicine 5 Hematology and Oncology Innsbruck Austria; Oncotyrol Center for Personalized Cancer Medicine Innsbruck Austria

Swiss Group for Clinical Cancer Research Bern Switzerland; Cantonal Hospital of St Gallen St Gallen Switzerland

Swiss Group for Clinical Cancer Research Bern Switzerland; Department of Medical Oncology Inselspital Bern Bern Switzerland

VU University Medical Center Amsterdam Netherlands

Lancet. 2018 Dec 23;390(10114):2744-2745. doi: 10.1016/S0140-6736(17)32343-7. PubMed

Br J Haematol. 2019 May;185(4):758-760. doi: 10.1111/bjh.15602. PubMed

References provided by Crossref.org

Circulating tumor DNA in Hodgkin lymphoma

Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group

See more in PubMed

ClinicalTrials.gov
NCT00515554